CureVac N.V. (CVAC) fair value analysis
Nasdaq · Updated 2026-10-19
CVAC price how computed
Valuation status
Reports in EURCVAC reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for CVAC until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $4.66
- Sector
- Healthcare
- 12-month range
- $4.12–$5.49
- Market cap
- $1.05B
- From 52-week high
- -15.1%
- Shares outstanding
- 225M
- Rank in Healthcare by quality score
- #142 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
CureVac N.V. is a biopharmaceutical company that develops messenger RNA based therapeutics and vaccines for infectious diseases and cancer. The company operates primarily in Europe and the United States.
CVAC currently ranks #142 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $1.05B
- Revenue (TTM)
- EUR 511M
- Net margin
- 37.9%
- EPS (TTM)
- EUR -0.49
- Gross margin
- 95.8%
- Revenue growth (3-yr avg)
- 1375.1%
- Shares outstanding
- 225M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 100 · overbought
- 50-day average
- $4.66
- 200-day average
- $4.68
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Earnings how computed
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-03 ▲ beat (+100.0%)
2025-09 ▲ beat (+53.3%)
2025-06 ▼ miss (-466.4%)
2025-03 ▲ beat (+17.7%)
2024-12 ▼ miss (-54.2%)
2024-09 ▲ beat (+145.9%)
2024-06 ▼ miss (-33.9%)
2024-03 ▼ miss (-116.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Consensus price target
- $5.41
- Target vs last price
- +16.1%
What our data shows for CVAC
- Shares are trading in the middle of their 12-month price range of $4.12–$5.49.
- The 14-day relative strength index sits at an overbought 100.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- CVAC's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent CVAC news
TickrTrends' derived news-sentiment signal for CVAC is currently leaning negative, computed from recent coverage.
What people are saying
Follow the CVAC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived quality indicator for CVAC declined this week, moving from a C grade to a D grade. This downgrade reflects a deterioration in the company's fundamental quality metrics as assessed through TickrTrends' analytical framework. The stock's valuation assessment remains incomplete pending full valuation analysis.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is CVAC stock undervalued?
CVAC reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for CVAC until same-currency inputs are available.
What is CVAC's TickrTrends verdict?
CVAC is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does CVAC compare to other Healthcare stocks?
CVAC ranks #142 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is CVAC overbought or oversold?
CVAC's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
Does CVAC usually beat earnings estimates?
Over its last 8 reported quarters CVAC beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.